Molbio Diagnostics IPO closes Day 3 with a strong 70.18 times subscription, led by massive QIB and NII demand

Molbio Diagnostics Limited's initial public offering (IPO) was subscribed 70.18 times by 5:24 PM on August 12, 2026. The public issue received bids for 57,25,36,170 shares against 81,58,529 shares available for subscription. The Qualified Institutional Buyers (QIBs) category led the demand with a subscription of 186.39 times, followed by the Non-Institutional Investors (NIIs) at 49.77 times, the Employee (EMP) portion at 13.14 times, and the Retail Individual Investors (RIIs) portion at 12.80 times.

Invest in Indian Markets and Unlock Future Potential With 5paisa!

Open Account Now

Subscription Status of Molbio Diagnostics IPO

Here are the subscription details for Molbio Diagnostics IPO Day 3, as of 5:24 PM:

Key Highlights – Day 3

• Overall subscription stood at 70.18 times on Day 3 (August 12, 2026).
• Qualified Institutional Buyers (QIBs) subscribed 186.39 times.
• Non-Institutional Investors (NIIs) subscribed 49.77 times.
• Retail Investors subscribed 12.80 times.
• Employee (EMP) portion subscribed 13.14 times.
• Anchor investors had fully subscribed their allocated portion, with 34,87,717 shares allotted.
• Overall, the IPO received bids for 57,25,36,170 shares against 81,58,529 shares available for subscription by 5:24 PM on Day 3.

Key Highlights – Day 2

• Overall subscription stood at 2.79 times on Day 2 (August 11, 2026).
• Qualified Institutional Buyers (QIBs) subscribed 1.39 times.
• Non-Institutional Investors (NIIs) subscribed 4.37 times.
• Retail Investors subscribed 2.90 times.
• Employee (EMP) portion subscribed 4.17 times.
• Anchor investors had fully subscribed their allocated portion, with 34,87,717 shares allotted.
• Overall, the IPO received bids for 2,27,41,578 shares against 81,58,529 shares available for subscription by 5:24 PM on Day 2.

Key Highlights – Day 1

• Overall subscription stood at 0.34 times on Day 1 (August 10, 2026).
• Qualified Institutional Buyers (QIBs) subscribed 0.63 times.
• Non-Institutional Investors (NIIs) subscribed 0.24 times.
• Retail Investors subscribed 0.21 times.
• Employee (EMP) portion subscribed 0.46 times.
• Anchor investors had fully subscribed their allocated portion before the issue opened, with 34,87,717 shares allotted.
• Overall, the IPO was subscribed 0.34 times on the opening day.

About Molbio Diagnostics Limited

Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour.